Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metformin and body weight.

A Golay1

  • 1Service of Therapeutic Education for Diabetes, Obesity and Chronic Diseases, Geneva University Hospital, Geneva, Switzerland. Alain.Golay@hcuge.ch

International Journal of Obesity (2005)
|July 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Weight loss maintenance].

Revue medicale suisse·2015
Same author

[How to lose weight effectively and in a sustainable manner: a review of current topics].

Revue medicale suisse·2015
Same author

[Food addiction].

Revue medicale suisse·2015
Same author

[The cure of type 2 diabetes and patient education].

Revue medicale suisse·2015
Same author

[Rehabilitation: a case for obese patients?].

Revue medicale suisse·2014
Same author

[The role of patient education in bariatric surgery].

Revue medicale suisse·2014
Same journal

Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East.

International journal of obesity (2005)·2026
Same journal

Expression of human endogenous retroviruses (HERVs) in the blood of adolescents with and without obesity.

International journal of obesity (2005)·2026
Same journal

Metabolic obesity phenotypic stability, dynamic transformation and risk of hypertension: a 10-year prospective cohort study in southwest China.

International journal of obesity (2005)·2026
Same journal

Obesity-induced intervertebral disk degeneration: pathophysiology and clinical implications.

International journal of obesity (2005)·2026
Same journal

Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.

International journal of obesity (2005)·2026
Same journal

Linking circulating chemerin and adiponectin to lipoprotein subclasses measured by <sup>1</sup>H-NMR spectroscopy in 3199 participants from the study of health in Pomerania.

International journal of obesity (2005)·2026
See all related articles

Metformin, an oral diabetes medication, aids in weight management for many type 2 diabetes patients and obese individuals. Its weight-neutral or weight-sparing effects offer a key advantage over other treatments.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Public Health

Background:

  • Overweight and obesity are primary risk factors for type 2 diabetes and associated cardiometabolic issues.
  • Many common antidiabetic medications contribute to weight gain, complicating disease management.
  • Metformin is a widely used oral antidiabetic agent with an extensive clinical history.

Purpose of the Study:

  • To review the impact of metformin on body weight, focusing on long-term studies (≥6 months).
  • To assess metformin's effects in both type 2 diabetic and obese nondiabetic populations.
  • To compare metformin's weight effects with other antidiabetic treatments and placebo.

Main Methods:

  • Systematic review of clinical studies evaluating metformin's effect on body weight.

Related Experiment Videos

  • Emphasis on studies with a duration of six months or longer.
  • Analysis of data from drug-naive type 2 diabetic patients and obese nondiabetic individuals.

    • Main Results:

    • Approximately 50% of studies in drug-naive type 2 diabetic patients showed significant weight loss with metformin.
    • Pooled analyses suggest no significant weight loss compared to placebo, but metformin mitigates insulin-induced weight gain.
    • Metformin demonstrated weight loss potential in obese nondiabetic populations, though long-term data are limited.

    Conclusions:

    • Metformin offers a weight-neutral or weight-sparing profile, a significant advantage in managing type 2 diabetes.
    • This contrasts with other first-line oral antidiabetic agents that frequently cause weight gain.
    • Further long-term studies in obese nondiabetic populations are warranted to fully elucidate metformin's role.